Listen on the go
CORRECT!
Next question
touchIMMUNOLOGY touchIMMUNOLOGY
Digestive Disorders

Eamonn Quigley, DDW 2021: Biotherapeutic Blautia Hydrogentrophica in IBS

Share this Video
Copy Link
Published Online: Jun 15th 2021

It was a pleasure to speak with Prof. Eamonn Quigley (Houston Methodist Hospital, Houston, TX, USA) about the phase 2 study of the single-strain live biotherapeutic, Blautia hydrogentrophica (Blautix), currently under investigation in irritable bowel syndrome (IBS).

His abstract entitled ‘A Phase 2 Study of Live Biotherapeutic Blautix in Irritable Bowel Syndrome (IBS) Patients with subtypes IBS-C and IBS-D’ (Sa607) was presented at DDW, 21-23 May 2021.

Questions

  1. What are the limitations of current treatments for IBS? (0:28)
  2. What is Blautix and what is the rationale for its use in the treatment of adults with IBS-C and IBS-D? (01:29)
  3. Could you tell us a little about the aims and design of the Phase II study you presented? (2:37)
  4. What are the efficacy and safety findings by region and what was the reason for the differences? (03:46)

Disclosures: Prof Eamonn Quigley has received research support, and acted as a consultant to 4D Pharma.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of DDW 2021 (Virtual).

Related Videos In Digestive Disorders
Digestive Disorders
Developed by Touch
UEG Young Talent Group – aims, key achievements and opportunities for early career gastroenterologists: Pilar Acedo
Watch Time: 7 mins

The UEG Young Talent Group (YTG) encourages young gastroenterologists to develop their careers through education, networking and training. We were delighted to catch up with UEG YTG Chair Dr. Pilar Acedo to discuss the training, education and professional opportunities available to young digestive healthcare specialists through UEG, the aims and key achievements of the UEG […]

Digestive Disorders, Inflammatory Bowel Disease
Developed by Touch
Highlights from Digestive Disease Week 2023: Gil Y. Melmed
Watch Time: 5 mins

Digestive Disease Week took place between 6-9 May, in this touchIMMUNOLOGY interview, we caught up with our Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) around his personal highlights from this year’s conference including non-pivotal clinical trial data analysing established inflammatory bowel disease (IBD) therapies such as vedolizumab, data around the […]

Digestive Disorders, Inflammatory Bowel Disease
Developed by Touch
Comparison study of upadacitinib and tofacitinib as induction treatment in ulcerative colitis: Gil Y. Melmed, DDW 2023
Watch Time: 5 mins

Upadacitinib and tofacitinib are both JAK inhibitors (JAKis) approved by the FDA for the treatment of ulcerative colitis. In this interview with Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) we discuss the aims, design and findings from his study presented at DDW 2023, comparing the efficacy and safety of these […]

Trending In Digestive Disorders:

UEG Young Talent Group – aims, key achievements and opportunities for early career gastroenterologists: Pilar Acedo
Digestive Disorders
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72